Skip to main content

Advertisement

SpringerLink
Log in

The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Erratum to this article was published on 10 May 2016

Abstract

No study has yet analyzed the impact of compliance with aromatase inhibitor(AI) treatments on fracture risk in a real-world setting in women with breast cancer. In this study, 8732 women with BC treated with AI, 8732 treated with tamoxifen (TAM), and 8732 age-matched women without BC selected from the Disease Analyzer database (IMS Health) were included. The main outcome measure was the impact of compliance with AI treatment on fracture risk. Demographic data included age, body mass index (BMI), and smoking status. Alcohol dependency, dementia, bone density, visual disturbances, diabetes, and use of corticosteroids were also assessed. Kaplan–Meier curves were used to analyze the proportion of patients with fracture over time, and multivariate Cox regression models were performed to assess the adjusted fracture risk. Mean age was 67.3 years. 17.6, 8.7, and 8.8 % of AI, TAM, and non-cancer patients, respectively, were diagnosed with fracture within 5 years after the index date (p < 0.001). The proportion of women receiving AI with fracture increased with treatment compliance, rising from 8.6 % when treatment persisted for less than a year to 18.0 % when it persisted for between 4 and 5 years (p < 0.001). By contrast, the proportion of fractures in women with BC receiving TAM for the same time periods decreased from 13.0 to 7.9 % (p < 0.001). The risk of fracture was higher in women with BC using AI than in the non-cancer group (HR = 3.00; p < 0.0001). Finally, current smoking status, BMI, dementia, and prescription of corticosteroids had significant impacts on fracture risk. Compliance with AI treatment in women with BC is associated with a clear increase in the risk of fracture, which is much higher than previously reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. World Cancer Research Fund International: Worldwide data. http://www.wcrf.org, 2015, Accessed 08 Feb 2015

  2. World Cancer Research Fund International: Breast cancer statistics. http://www.wcrf.org, 2015, Accessed on 08 Feb 2015

  3. Hadji P, Ziller V, Kyvernitakis J et al (2013) Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 138:185–191. doi:10.1007/s10549-013-2417-1

    Article  CAS  PubMed  Google Scholar 

  4. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary Breast cancer. J Clin Oncol 21:602–606. doi:10.1200/JCO.2003.07.071

    Article  CAS  PubMed  Google Scholar 

  5. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271. doi:10.1093/jnci/dji250

    Article  CAS  PubMed  Google Scholar 

  6. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet Lond Engl 369:559–570. doi:10.1016/S0140-6736(07)60200-1

    Article  CAS  Google Scholar 

  7. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141. doi:10.1016/S1470-2045(10)70257-6

    Article  CAS  PubMed  Google Scholar 

  8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet Lond Engl. doi:10.1016/S0140-6736(15)61074-1

    Google Scholar 

  9. Hadji P, Gnant M, Body JJ et al (2012) Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 38:798–806. doi:10.1016/j.ctrv.2012.02.008

    Article  CAS  PubMed  Google Scholar 

  10. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53. doi:10.1016/S1470-2045(07)70385-6

    Article  Google Scholar 

  11. Mincey BA, Duh MS, Thomas SK et al (2006) Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7:127–132. doi:10.3816/CBC.2006.n.021

    Article  CAS  PubMed  Google Scholar 

  12. Chen Z, Maricic M, Bassford TL et al (2005) Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 165:552–558. doi:10.1001/archinte.165.5.552

    Article  PubMed  Google Scholar 

  13. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156–166. doi:10.1016/j.critrevonc.2009.02.001

    Article  PubMed  Google Scholar 

  14. Hadji P, Blettner M, Harbeck N et al (2013) The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24:1505–1512. doi:10.1093/annonc/mds653

    Article  CAS  PubMed  Google Scholar 

  15. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497. doi:10.1056/NEJMra050100

    Article  CAS  PubMed  Google Scholar 

  16. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128. doi:10.1200/JCO.2009.25.9655

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ogdie A, Langan SM, Parkinson J et al. (2012) Medical record databases. In: MPH BLSM, MSCE SEKM, PHARMD SH (eds) Pharmacoepidemiology. Wiley-Blackwell, pp 224–243

  18. Cancer Research UK: Breast cancer statistics. http://www.cancerresearchuk.org, 2015, Accessed 08 Feb 2015

  19. Masood S (1992) Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol 8:475–491

    Article  CAS  PubMed  Google Scholar 

  20. Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. doi:10.1200/JCO.2013.54.2258

    Article  PubMed  Google Scholar 

  21. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet Lond Engl 381:805–816. doi:10.1016/S0140-6736(12)61963-1

    Article  CAS  Google Scholar 

  22. Fallowfield L, Atkins L, Catt S et al (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205–210. doi:10.1093/annonc/mdj044

    Article  CAS  PubMed  Google Scholar 

  23. Barron TI, Connolly R, Bennett K et al (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832–839. doi:10.1002/cncr.22485

    Article  CAS  PubMed  Google Scholar 

  24. Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562. doi:10.1200/JCO.2007.11.5451

    Article  CAS  PubMed  Google Scholar 

  25. Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. doi:10.1093/annonc/mdr017

    PubMed  Google Scholar 

  26. Cummings SR, Browner WS, Bauer D et al (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339:733–738. doi:10.1056/NEJM199809103391104

    Article  CAS  PubMed  Google Scholar 

  27. Dawson-Hughes B, Looker AC, Tosteson ANA et al (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23:811–820. doi:10.1007/s00198-011-1694-y

    Article  CAS  PubMed  Google Scholar 

  28. Hamilton A, Piccart M (1999) The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10:377–384

    Article  CAS  PubMed  Google Scholar 

  29. Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73–82. doi:10.1016/j.critrevonc.2008.07.013

    Article  PubMed  Google Scholar 

  30. Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet 386:433–443. doi:10.1016/S0140-6736(15)60995-3

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IMS HEALTH GmbH & Co. OHG, Epidemiology, Real World Evidence Solutions, Darmstädter Landstraße 108, 60598, Frankfurt, Germany

    Nina Schimdt & Karel Kostev

  2. Department of Biology, École Normale Supérieure de Lyon, Lyon, France

    Louis Jacob

  3. Department of Oncology, University of Sheffield, Sheffield, UK

    Robert Coleman

  4. Nordwest Hospital, Frankfurt, Germany

    Peyman Hadji

  5. Department of Gynaecology, Gynaecological Endocrinology and Oncology, Philipps-University of Marburg, Marburg, Germany

    Peyman Hadji

Authors
  1. Nina Schimdt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louis Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karel Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peyman Hadji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karel Kostev.

Ethics declarations

Conflict of interest

NS, LJ, RC, PH, and KK have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schimdt, N., Jacob, L., Coleman, R. et al. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 155, 151–157 (2016). https://doi.org/10.1007/s10549-015-3661-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3661-3

Keywords

Search

Navigation